TGFB1 and ductal breast carcinoma in situ: This therapeutic approach could also be useful in the context of DCIS tumors with a high-risk of invasive progression upon standard treatment, that we identified as having a depletion in Detox-iCAF and an enrichment in TGFβ-myCAF.